AI-Ready GMP Quality Systems: Regulatory Governance for Machine Learning in Pharmaceutical Manufacturing

Abstract

Artificial intelligence (AI) and machine learning (ML) have transitioned from experimental pursuits to production-ready infrastructure across pharmaceutical manufacturing, quality control, and supply chain operations. Nevertheless, their integration into Good Manufacturing Practice (GMP)-regulated environments is hindered by a set of challenges that are qualitatively distinct from those encountered in traditional software development: stochasticity introduced during model training, opaque decision-making processes, dependence on training data at a scale and complexity that surpasses conventional process models, and, in the case of adaptive implementations, the potential for in-service self-modification. This chapter investigates the regulatory frameworks governing AI/ML within pharmaceutical GMP settings, drawing on current guidance from the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Medicines and Healthcare Products Regulatory Agency (MHRA), and the International Council for Harmonisation (ICH). It traces the evolution of each agency’s approach, identifies areas of convergence and divergence, and assesses the adequacy of existing frameworks for the most demanding AI applications. Key themes such as compliance, algorithmic validation, ALCOA+ data integrity, quality risk management, lifecycle governance, and human oversight are examined through the lens of real-world implementations at companies including Pfizer, Novartis, AstraZeneca, Sanofi, and Roche. Regulatory gaps in continuous-learning systems, standards for explainability, and global harmonization of definitions are identified, along with a proposed policy roadmap for the future. The chapter concludes with practical guidance for pharmaceutical organizations aiming to deploy AI/ML responsibly within their existing quality systems.